Volume 7.06 | Feb 19

Mammary Cell News 7.06 February 19, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
 
TOP STORY
One-Two Punch Catches Cancer Cells in Vulnerable State
Researchers were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models. [Press release from Brigham and Women’s Hospital discussing online publication in Nature Communications] Press Release | Abstract
MammoCult™: Most Published Mammosphere & Tumorsphere Culture Medium (Commercially Available) FREE Sample Request
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Epigenetic and Transcriptional Determinants of the Human Breast
Scientists generated epigenomic and transcriptional profiles from primary human breast cell types isolated from disease-free human subjects. From these data they define a comprehensive human breast transcriptional network, including a set of myoepithelial- and luminal epithelial-specific intronic retention events. [Nat Commun] Full Article | Press Release

APOBEC3B Expression in Breast Cancer Reflects Cellular Proliferation, While a Deletion Polymorphism Is Associated with Immune Activation
Investigators confirmed that APOBEC3B (A3B) expression is associated with aggressive clinicopathologic characteristics and adverse outcomes and show that A3B expression is highly correlated with proliferative features (mitosis and cell cycle-related gene expression) in breast and 15 of 16 other solid tumor types. [Proc Natl Acad Sci USA] Abstract | Full Article

Wnt/β-Catenin Small Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-Like Cells
Researchers show that the level of Wnt/β-catenin signaling in breast cancer stem cells is relatively higher than in bulk tumor cells, contributing to a relatively higher level of therapeutic resistance. [Cancer Res] Abstract

Cytoplasmic p27 Promotes Epithelial-Mesenchymal Transition and Tumor Metastasis via STAT3-Mediated Twist1 Upregulation
Cell cycle-defective phosphomimetic phosphorylation of p27 at threonine 157 (T157) and T198 activates STAT3 (signal transducer and activator of transcription 3) to induce a TWIST1-dependent epithelial-mesenchymal transition in human mammary epithelial cells and increases breast and bladder cancer invasion and metastasis. [Oncogene] Full Article

PEGylated-Thymoquinone-Nanoparticle Mediated Retardation of Breast Cancer Cell Migration by Deregulation of Cytoskeletal Actin Polymerization through miR-34a
Scientists provide direct evidence that thymoquinone (TQ)-nanoparticles showed more efficiency in killing cancer cells as well as proved to be less toxic to normal cells at a significantly lower dose than TQ. [Biomaterials] Abstract

Ski Regulates Hippo and TAZ Signaling to Suppress Breast Cancer Progression
Researchers investigated the mechanism(s) underlying the tumor suppressor activity of Ski and found that Ski suppressed the activity of the Hippo signaling effectors TAZ and YAP to inhibit breast cancer progression. [Sci Signal] Abstract

The Tyrosine Phosphatase PTPN14 (Pez) Inhibits Metastasis by Altering Protein Trafficking
Investigators found that the tyrosine phosphatase PTPN14 suppressed metastasis by reducing intracellular protein trafficking through the secretory pathway. Knocking down PTPN14 in tumor cells or injecting the peritoneum of mice with conditioned medium from PTPN14-deficient cell cultures promoted the growth and metastasis of breast cancer xenografts. [Sci Signal] Abstract

CLINICAL RESEARCH

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. [New Engl J Med] Full Article | Press Release

Evidence for Biological Effects of Metformin in Operable Breast Cancer: Biomarker Analysis in a Pre-Operative Window of Opportunity Randomized Trial
Investigators examined biomarker effects of metformin in primary breast cancer in a preoperative window of opportunity trial. Non-diabetic women with operable invasive breast cancer were randomized to receive open label pre-operative metformin or as controls. [Breast Cancer Res Treat] Abstract

Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
 
REVIEWS
Management of Locally Advanced Breast Cancer—Perspectives and Future Directions
Locally advanced breast cancer (LABC) constitutes a heterogeneous entity that includes advanced-stage primary tumors, cancers with extensive nodal involvement and inflammatory breast carcinomas. The authors discuss the current state of the art and possible future treatment strategies for patients with LABC. [Nat Rev Clin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
SCIENCE NEWS
Generex Provides Update on Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
Generex Biotechnology Corporation announced that results of the last pre-specified analysis of data from a Phase II study of a novel cancer vaccine designed to reduce the risk of relapse in patients who have had breast cancer corroborate qualitatively prior results from the primary analysis conducted in January of 2014. [Press release from Generex Biotechnology Corporation discussing research to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
 
INDUSTRY NEWS
Looking Back on Two Decades of Breast Cancer Treatment: Targeted Therapy and Improved Surgical Procedures are Key Enhancements
The National Comprehensive Cancer Network® (NCCN®) has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer—one of the original NCCN Guidelines® published in November 1996. [The National Comprehensive Cancer Network] Press Release

Kaul Foundation Donates $7 Million for UAB Personalized Medicine Institute
The Hugh Kaul Foundation has donated $7 million to the University of Alabama at Birmingham (UAB) to establish the Hugh Kaul Personalized Medicine Institute at UAB. [University of Alabama at Birmingham] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW American Association for Cancer Research (AACR) Annual Meeting 2015
April 18-22, 2015
Philadelphia, United States

NEW Precision Cancer Biology and Medicine
May 4-8, 2015
Suzhou, China

NEW ISSCR 2015 Annual Meeting
June 24-27, 2015
Stockholm, Sweden

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Position – Breast Cancer Biology (University of Pennsylvania)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Clinician Scientist (National University of Singapore)

Postdoctoral Associate – LincRNAs in Tumorigenesis (Fox Chase Cancer Center)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Postdoctoral Positions – Cancer Bioengineering and Cancer Biology (University of Minnesota)

Director of Research (Dr. Susan Love Research Foundation)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us